Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma
This study is currently recruiting participants.
Verified April 2013 by Memorial Sloan-Kettering Cancer Center
Sponsor:
Memorial Sloan-Kettering Cancer Center
Collaborators:
Genentech
Children's Mercy Hospital Kansas City
Penn State University
University of Colorado Health Sciences Center and The Children's Hospital
Sidney Kimmel Comprehensive Cancer Center
Phoenix Children's Hospital Center for Cancer & Blood Disorders
Alberta Children's Hospital
MD Anderson Cancer Center Orlando
M.D. Anderson Cancer Center
Information provided by (Responsible Party):
Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT01492673
First received: December 12, 2011
Last updated: April 2, 2013
Last verified: April 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study is currently recruiting participants. |
|---|---|
| Estimated Study Completion Date: | December 2014 |
| Estimated Primary Completion Date: | December 2014 (Final data collection date for primary outcome measure) |